Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oncologist. 2020 Oct;25(10):822-825. doi: 10.1634/theoncologist.2020-0760. Epub 2020 Aug 27.
MET exon 14 skipping alterations (METex14) represent one of the newest discovered driver oncogene alterations for non-small cell lung cancer (NSCLC), which serve to define a distinct elderly patient population. New challenges in detection and treatment have emerged. In the last 15 years, the successes of tumor molecular profiling and therapeutic stratification in patients with advanced-stage disease have made NSCLC a poster child in the era of precision medicine. Each of the oncogenic drivers defines a distinct patient population. The selection of treatments based on oncogenic drivers such as EGFR, ALK, and ROS1, among others, has been transformative in terms of the duration and quality of life for patients with NSCLC receiving effective inhibitors. METex14 have emerged as one of the newest additions of driver oncogenes for NSCLC.
MET 外显子 14 跳跃改变（METex14）是非小细胞肺癌（NSCLC）中最新发现的驱动基因改变之一，它定义了一个独特的老年患者群体。在检测和治疗方面出现了新的挑战。在过去的 15 年中，晚期疾病患者的肿瘤分子谱分析和治疗分层的成功使 NSCLC 成为精准医学时代的典范。每个致癌驱动因子都定义了一个独特的患者群体。基于 EGFR、ALK 和 ROS1 等致癌驱动因子选择治疗方法，对于接受有效抑制剂治疗的 NSCLC 患者的生存期和生活质量产生了变革性的影响。METex14 已成为 NSCLC 最新的驱动基因之一。
